Darunavir in Swedish Preliminary
Injunction Proceedings
Recently, the Paris High Court decided for a preliminary
injunction against the commercialisation of Darunavir by Sandoz, the SPC Blog report can be found here. In
parallel proceedings, the Swedish Patent and Market Appeal Court has come to
the opposite conclusion, and found that that the contested SPC would most
likely be found invalid and thus denied a request for a preliminary injunction.
Hampus Rystedt from Zacco has kindly provided the following summary of the case…..
Report: Jury orders Takeda to pay
Bayer $155M over hemophilia drug
A U.S. jury has ordered Takeda Pharmaceutical’s Baxalta unit
to pay Bayer AG $155.19 million for infringing a patent related to a Baxalta
hemophilia treatment. According to Reuters, jurors in the federal court in
Wilmington, Del., reached their verdict on the seventh day of a trial after
rejecting Baxalta’s argument that the June 2016 patent on the treatment, Adynovate, was invalid……
Roche denied India patent for powder
formulation for anti-HIV drug Valcyte
In a setback to Swiss pharma major F Hoffmann-La Roche
(Roche), the Indian patent office has rejected the company’s application for a
powder formulation for Valganciclovir,
its anti-viral drug for HIV patients sold under brand name Valcyte. The Chennai
patent office refused the patent for the formulation on the ground of lack of
novelty……
A Second Opposition Is Filed against
Janssen’s Patent Application for the Fumarate Salt Form of Bedaquiline
Multiple news outlets recently reported about a pre-grant
patent opposition filed by two TB survivors, with support from MSF, against a
patent application filed by Janssen for a salt form of its experimental TB drug
bedaquiline. In a press note put out
by MSF, it was claimed that this opposition “…is the first ever challenge
against a TB drug patent in India”. This is a factually incorrect statement…..
Diagnosis: Ineligible
Mayo is involved in another diagnostic method patent dispute
— and again has come out on-top with a finding that the asserted patent claims are
ineligible under 35 U.S.C. 101. That district court finding has now been
affirmed on appeal, although subject to a strong dissent from Judge Newman……
Full Fed. Circ. Won't Review $20M
Cialis Marketing Verdict
The full Federal Circuit on Tuesday declined to review
whether a panel erred by upholding a $20 million infringement verdict entered
in Texas federal court against Eli Lilly & Co. for...
Read more @ https://www.law360.com/ip/articles/1125994/full-fed-circ-won-t-review-20m-cialis-marketing-verdict
Fed Circuit refusal paves way for
Suboxone generics
Rivals of British pharmaceutical company Indivior will soon
be able to sell generic versions of opioid addiction treatment Suboxone film (buprenorphine and naloxone) following a
ruling of the US Court of Appeals for the Federal Circuit….
Read more @ https://www.lifesciencesipreview.com/news/fed-circuit-refusal-paves-way-for-suboxone-generics-3363
No comments:
Post a Comment